Resolute Oncology Inc. Information

Lower cost, affordable drugs and biopharmaceuticals are now an imminent reality in the global oncology market due to ongoing and imminent patent expirations and financial pressures on governments and payers. This reality, coupled with ever increasing pressure and demand for more competitively priced biopharmaceutical products in all global markets signals a considerable emerging new commercial opportunity. ROI is focused on developing improved versions of these compounds along with value-added customer solutions that will drive market share. Resolute Oncology Inc (ROI) is positioning itself to be at the forefront of this opportunity, establishing a competitive pipeline of value-added oncology products for the North American and European markets. A highly experienced management team will execute the operational, regulatory and commercialization plans to launch cost-effective, value-added, life-saving oncology products.